A phase 1b/2 clinical trial (NCT03684811), investigating the effect of the 5-azacytidine in combination with Olutasidenib on glioblastoma patients with IDH1 mutations is ongoing, and the results are eagerly awaited [75]. This evidence concerns the gene IDH1 and glioblastoma.